Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Apremilast may help treat hair loss in alopecia areata.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This study observed that apremilast treatment improved skin lesions and reduced pruritus in patients with chronic, severe atopic dermatitis and one case of hand and foot dermatitis.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This review of seborrheic dermatitis highlights the role of complex immunoinflammatory processes in its pathogenesis and discusses emerging treatments, such as PDE4 inhibitors, JAK inhibitors, and microbiome-targeted therapies, which may benefit patients with severe or treatment-resistant forms, according to the authors.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.

This case report suggests that crisaborole may be an effective alternative treatment for alopecia areata in pediatric patients, showing significant hair regrowth after two weeks in a 10-year-old girl.

In this review, researchers reported that pyroptosis, a type of inflammatory cell death linked to inflammasome activity, is a key factor in the pathogenesis of alopecia areata and may present new therapeutic opportunities, though most treatments are still in early research stages.

This study reviews current pharmacological treatments for alopecia, highlighting minoxidil, 5α-reductase inhibitors, JAK inhibitors, and other agents, and notes ongoing research aimed at improving their effectiveness and safety profiles.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.

This study found that actively targeted AN2728-loaded nanocarriers reduced inflammation and improved skin condition in a mouse model of psoriasiform inflammation compared to free drug and non-targeted nanoparticles.

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

This review discusses the connections between atopic dermatitis and alopecia areata, emphasizing shared mechanisms and potential overlapping treatments, but it does not report new clinical findings.

This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

In this research, caffeine's versatile pharmacological actions were highlighted, demonstrating its stimulant, bronchodilator, diuretic, and potential anticancer effects through interactions with adenosine receptors, phosphodiesterase, and renal tubules, revealing valuable insights for drug development and therapeutic applications in medicine.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.